G Grunberger
Overview
Explore the profile of G Grunberger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
869
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grunberger G, Chen L, Rodriguez A, Tinahones F, Jacober S, Bue-Valleskey J
Diabetes Obes Metab
. 2016 Oct;
18 Suppl 2:34-42.
PMID: 27723225
Aims: Basal insulin peglispro (BIL) has a longer duration of action than conventional insulin analogues and a hepato-preferential mechanism of action. This study assessed whether BIL was non-inferior to isophane...
2.
Grunberger G, Forst T, Fernandez Lando L, Pechtner V, Shaginian R, Jia N, et al.
Diabet Med
. 2015 Jul;
33(3):391-4.
PMID: 26179454
Aims: To assess whether early measures of fasting blood glucose predict later glycaemic response with once-weekly dulaglutide in patients with Type 2 diabetes mellitus. Methods: Post hoc analyses were conducted...
3.
Grunberger G
Diabetes Obes Metab
. 2013 Mar;
15 Suppl 1:1-5.
PMID: 23448196
Insulin replacement therapy corrects a core defect of diabetes pathophysiology. Since its introduction as a therapeutic modality almost 100 years ago, insulin therapy has undergone remarkable changes in purity and...
4.
Grunberger G, Chang A, Garcia Soria G, Botros F, Bsharat R, Milicevic Z
Diabet Med
. 2012 Jul;
29(10):1260-7.
PMID: 22804250
Aims: Evaluate dose-dependent effects of once-weekly dulaglutide, a glucagon-like peptide-1 analogue, on glycaemic control in patients with Type 2 diabetes treated with lifestyle measures with or without previous metformin. Methods:...
5.
Sima A, Grunberger G, Jornvall H, Wahren J
Int J Exp Diabetes Res
. 2002 Oct;
2(2):145-51.
PMID: 12369718
In recent years the physiological role of the proinsulin C-peptide has received increasing attention, focusing on the potential therapeutic value of C-peptide replacement in preventing and ameliorating type 1 diabetic...
6.
7.
Grunberger G, Qiang X, Li Z, Mathews S, Sbrissa D, Shisheva A, et al.
Diabetologia
. 2001 Nov;
44(10):1247-57.
PMID: 11692173
Aims/hypothesis: C-peptide, released by the beta-cells of pancreatic islets, elicits salutary responses in Type I (insulin-dependent) diabetes mellitus but the molecular mechanisms behind these effects are not known. We assessed...
8.
Sima A, Zhang W, Sugimoto K, Henry D, Li Z, Wahren J, et al.
Diabetologia
. 2001 Aug;
44(7):889-97.
PMID: 11508275
Aims/hypothesis: Insulin and C-peptide exert neuroprotective effects and are deficient in Type I (insulin-dependent) diabetes mellitus but not in Type II (non-insulin-dependent) diabetes mellitus. These studies were designed to test...
9.
Cintron V, Ko M, Chi K, Gross J, Srinivas P, Goustin A, et al.
Int J Exp Diabetes Res
. 2001 Jul;
1(4):249-63.
PMID: 11467416
Fetuin/alpha2-HS glycoprotein (alpha2-HSG) homologs have been identified in several species including rat, sheep, pig, rabbit, guinea pig, cattle, mouse and human. Multiple physiological roles for these homologs have been suggested,...
10.
Phillips L, Grunberger G, Miller E, Patwardhan R, Rappaport E, Salzman A
Diabetes Care
. 2001 Feb;
24(2):308-15.
PMID: 11213884
Objective: To determine the efficacy of rosiglitazone compared with placebo in reducing hyperglycemia. Research Design And Methods: After a 4-week placebo run-in period, 959 patients were randomized to placebo or...